Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2018

Bellone Stefania, Buza Natalia, Choi Jungmin, Zammataro Luca, Gay Laurie, Elvin Julia, Rimm David L, Liu Yuting, Ratner Elena S, Schwartz Peter E, Santin Alessandro D

Abstract excerpt

Purpose: Ovarian carcinoma no longer responsive to surgery and chemotherapy remains an incurable disease. Alternative therapeutic options remain desperately needed.Patients and Methods: We describe a heavily pretreated patient with ovarian cancer with recurrent disease experiencing a remarkable clinical response to treatment with the anti-PD1 immune checkpoint inhibitor pembrolizumab. The clinical, pathological,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Gene Rearrangement

Share to Molecular Targeted Therapy

Share to Positron Emission Tomography Computed Tomography

Share to Programmed Cell Death 1 Receptor

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 29351920
DOI: 10.1158/1078-0432.CCR-17-1805
PMCID: PMC6050068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.PMID 29351920Read ↗

Recurrent <i>PD-L1</i> Structural Rearrangements in Natural Killer/T Cell Lymphoma Patients with Complete Response to PD-1 Blockade TherapySemantic proximity Read ↗

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.Semantic proximity Read ↗

Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.Semantic proximity Read ↗

Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Mutation.Semantic proximity Read ↗

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.Semantic proximity Read ↗

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerSemantic proximity Read ↗

The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes.Semantic proximity Read ↗

Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.Semantic proximity Read ↗

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphomaSemantic proximity Read ↗

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinomaSemantic proximity Read ↗

Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancerSemantic proximity Read ↗

<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.